The therapeutic effect of S1P receptor modulators in MS was later shown to also have more complex roots in S1P1-mediated amelioration of BBB dysfunction and in S1P1 and S1P5-mediated direct action on CNS cellular survival and myelination [279,283]. Here, S1PR1 is linked to myeloid sarcoma.